{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T12:18:06Z","timestamp":1792153086480,"version":"4.4.0"},"reference-count":79,"publisher":"Japan Neurosurgical Society","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Neurol. Med. Chir.(Tokyo)"],"published-print":{"date-parts":[[2024,8,15]]},"DOI":"10.2176\/jns-nmc.2024-0067","type":"journal-article","created":{"date-parts":[[2024,6,18]],"date-time":"2024-06-18T22:11:08Z","timestamp":1718748668000},"page":"299-308","source":"Crossref","is-referenced-by-count":12,"title":["Historical Development of Diagnostic Criteria for NF2-related Schwannomatosis"],"prefix":"10.2176","volume":"64","author":[{"given":"Ryota","family":"TAMURA","sequence":"first","affiliation":[{"name":"Department of Neurosurgery, Keio University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"YO","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Keio University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"TODA","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Keio University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"971","reference":[{"key":"1","unstructured":"1) Kresak JL, Walsh M: Neurofibromatosis: a review of NF1, NF2, and Schwannomatosis. <i>J Pediatr Genet<\/i> 5: 98-104, 2016"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Riccardi VM: Neurofibromatosis: clinical heterogeneity. <i>Curr Probl Cancer<\/i> 7: 1-34, 1982","DOI":"10.1016\/S0147-0272(82)80016-0"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Ruggieri M, Pratic\u00f2 AD, Caltabiano R, Polizzi A: Early history of the different forms of neurofibromatosis from ancient Egypt to the British Empire and beyond: first descriptions, medical curiosities, misconceptions, landmarks, and the persons behind the syndromes. <i>Am J Med Genet A<\/i> 176: 515-550, 2018","DOI":"10.1002\/ajmg.a.38486"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Asthagiri AR, Parry DM, Butman JA, et al.: Neurofibromatosis type 2. <i>Lancet<\/i> 373: 1974-1986, 2009","DOI":"10.1016\/S0140-6736(09)60259-2"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Evans DGR: Neurofibromatosis type 2 (NF2): a clinical and molecular review. <i>Orphanet J Rare Dis<\/i> 4: 16, 2009","DOI":"10.1186\/1750-1172-4-16"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Evans DG: Neurofibromatosis 2 [Bilateral acoustic neurofibromatosis, central neurofibromatosis, NF2, neurofibromatosis type II]. <i>Genet Med<\/i> 11: 599-610, 2009","DOI":"10.1097\/GIM.0b013e3181ac9a27"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Lallemand D, Manent J, Couvelard A, et al.: Merlin regulates transmembrane receptor accumulation and signaling at the plasma membrane in primary mouse Schwann cells and in human schwannomas. <i>Oncogene<\/i> 28: 854-865, 2009","DOI":"10.1038\/onc.2008.427"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Martuza RL, Eldridge R: Neurofibromatosis 2 (bilateral acoustic neurofibromatosis). <i>N Engl J Med<\/i> 318: 684-688, 1988","DOI":"10.1056\/NEJM198803173181106"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Plotkin SR, Messiaen L, Legius E, et al.: Updated diagnostic criteria and nomenclature for neurofibromatosis type 2 and schwannomatosis: an international consensus recommendation. <i>Genet Med<\/i> 24: 1967-1977, 2022","DOI":"10.1212\/WNL.98.18_supplement.3996"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Lloyd SKW, Evans DGR: Neurofibromatosis type 2 (NF2): diagnosis and management. <i>Handb Clin Neurol<\/i> 115: 957-967, 2013","DOI":"10.1016\/B978-0-444-52902-2.00054-0"},{"key":"11","unstructured":"11) Von Recklinghausen FD: Ueber die Multiplen Fibrome der Hautund Inhre Beziehung zu den Multiplen Neuromen. Berlin, Hirschwald, 1882"},{"key":"12","unstructured":"12) Wishart JH: Case of tumours in the skull, dura mater, and brain. <i>Edinb Med Surg J<\/i> 18: 393-397, 1822"},{"key":"13","unstructured":"13) Legius E, Messiaen L, Wolkenstein P, et al.: Revised diagnostic criteria for neurofibromatosis type 1 and Legius syndrome: an international consensus recommendation. <i>Genet Med<\/i> 23: 1506-1513, 2021"},{"key":"14","unstructured":"14) Cushing H: Tumors of the Nervus Acusticus and the Syndrome of the Cerebellopontile Angle. Philadelphia, W B Saunders Company, 1917, pp viii"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Feiling A, Ward EA: Familial form of acoustic tumour. <i>BMJ<\/i> 10: 496-497, 1920","DOI":"10.1136\/bmj.1.3093.496"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Gardner WJ, Frazier CH: Bilateral acoustic neurofibromas: a clinical study and field survey of a family of five generations with bilateral deafness in thirty eight members. <i>Arch Neurol Psychiatry<\/i> 23: 266-302, 1930","DOI":"10.1001\/archneurpsyc.1930.02220080050005"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Iwabuchi S, Tanita T, Koike K, Fujimura S: Familial neurilemmomatosis: report of a case. <i>Surg Today<\/i> 23: 816-819, 1993","DOI":"10.1007\/BF00311626"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Rouleau GA, Wertelecki W, Haines JL, et al.: Genetic linkage of bilateral acoustic neurofibromatosis to a DNA marker on chromosome 22. <i>Nature<\/i> 329: 246-248, 1987","DOI":"10.1038\/329246a0"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Seizinger BR, Rouleau GA, Ozelius LJ, et al.: Genetic linkage of von Recklinghausen neurofibromatosis to the nerve growth factor receptor gene. <i>Cell<\/i> 49: 589-594, 1987","DOI":"10.1016\/0092-8674(87)90534-4"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Neurofibromatosis. Conference statement. National Institutes of Health Consensus Development Conference. <i>Arch Neurol<\/i> 45: 575-578, 1988","DOI":"10.1001\/archneur.1988.00520290115023"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) Mulvihill JJ, Parry DM, Sherman JL, Pikus A, Kaiser-Kupfer MI, Eldridge R: NIH conference. Neurofibromatosis 1 (Recklinghausen disease) and neurofibromatosis 2 (bilateral acoustic neurofibromatosis). An update. <i>Ann Intern Med<\/i> 113: 39-52, 1990","DOI":"10.7326\/0003-4819-113-1-39"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) Consensus Development Panel: National Institutes of Health consensus development conference statement on acoustic neuroma, December 11-13, 1991. <i>Arch Neurol<\/i> 51: 201-207, 1994","DOI":"10.1001\/archneur.1994.00540140115021"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) Baser ME, Friedman JM, Wallace AJ, Ramsden RT, Joe H, Evans DG: Evaluation of clinical diagnostic criteria for neurofibromatosis 2. <i>Neurology<\/i> 59: 1759-1765, 2002","DOI":"10.1212\/01.WNL.0000035638.74084.F4"},{"key":"24","unstructured":"24) Evans DG, Huson SM, Donnai D, et al.: A clinical study of type 2 neurofibromatosis. <i>Q J Med<\/i> 84: 603-618, 1992"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25) Gutmann DH, Aylsworth A, Carey JC, et al.: The diagnostic evaluation and multidisciplinary management of neurofibromatosis 1 and neurofibromatosis 2. <i>JAMA<\/i> 278: 51-57, 1997","DOI":"10.1001\/jama.278.1.51"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26) Baser ME, Friedman JM, Joe H, et al.: Empirical development of improved diagnostic criteria for neurofibromatosis 2. <i>Genet Med<\/i> 13: 576-581, 2011","DOI":"10.1097\/GIM.0b013e318211faa9"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27) Evans DG, Mason S, Huson SM, Ponder M, Harding AE, Strachan T: Spinal and cutaneous schwannomatosis is a variant form of type 2 neurofibromatosis: a clinical and molecular study. <i>J Neurol Neurosurg Psychiatry<\/i> 62: 361-366, 1997","DOI":"10.1136\/jnnp.62.4.361"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28) MacCollin M, Braverman N, Viskochil D, et al.: A point mutation associated with a severe phenotype of neurofibromatosis 2. <i>Ann Neurol<\/i> 40: 440-445, 1996","DOI":"10.1002\/ana.410400313"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29) MacCollin M, Woodfin W, Kronn D, Short MP: Schwannomatosis: a clinical and pathologic study. <i>Neurology<\/i> 46: 1072-1079, 1996","DOI":"10.1212\/WNL.46.4.1072"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30) Wolkenstein P, Benchikhi H, Zeller J, Wechsler J, Revuz J: Schwannomatosis: a clinical entity distinct from neurofibromatosis type 2. <i>Dermatology<\/i> 195: 228-231, 1997","DOI":"10.1159\/000245948"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31) MacCollin M, Chiocca EA, Evans DG, et al.: Diagnostic criteria for schwannomatosis. <i>Neurology<\/i> 64: 1838-1845, 2005","DOI":"10.1212\/01.WNL.0000163982.78900.AD"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32) Baser ME, Friedman JM, Evans DGR: Increasing the specificity of diagnostic criteria for schwannomatosis. <i>Neurology<\/i> 66: 730-732, 2006","DOI":"10.1212\/01.wnl.0000201190.89751.41"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33) Plotkin SR, Blakeley JO, Evans DG, et al.: Update from the 2011 International Schwannomatosis workshop: from genetics to diagnostic criteria. <i>Am J Med Genet A<\/i> 161A: 405-416, 2013","DOI":"10.1002\/ajmg.a.35760"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34) Tinschert S, Naumann I, Stegmann E, et al.: Segmental neurofibromatosis is caused by somatic mutation of the neurofibromatosis type 1 (NF1) gene. <i>Eur J Hum Genet<\/i> 8: 455-459, 2000","DOI":"10.1038\/sj.ejhg.5200493"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35) Hulsebos TJM, Plomp AS, Wolterman RA, Robanus-Maandag EC, Baas F, Wesseling P: Germline mutation of INI1\/SMARCB1 in familial schwannomatosis. <i>Am J Hum Genet<\/i> 80: 805-810, 2007","DOI":"10.1086\/513207"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36) Jacoby LB, Jones D, Davis K, et al.: Molecular analysis of the NF2 tumor-suppressor gene in schwannomatosis. <i>Am J Hum Genet<\/i> 61: 1293-1302, 1997","DOI":"10.1086\/301633"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37) MacCollin M, Willett C, Heinrich B, et al.: Familial schwannomatosis: exclusion of the NF2 locus as the germline event. <i>Neurology<\/i> 60: 1968-1974, 2003","DOI":"10.1212\/01.WNL.0000070184.08740.E0"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38) Boyd C, Smith MJ, Kluwe L, Balogh A, Maccollin M, Plotkin SR: Alterations in the SMARCB1 (INI1) tumor suppressor gene in familial schwannomatosis. <i>Clin Genet<\/i> 74: 358-366, 2008","DOI":"10.1111\/j.1399-0004.2008.01060.x"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39) Hadfield KD, Newman WG, Bowers NL, et al.: Molecular characterisation of SMARCB1 and NF2 in familial and sporadic schwannomatosis. <i>J Med Genet<\/i> 45: 332-339, 2008","DOI":"10.1136\/jmg.2007.056499"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40) Sestini R, Bacci C, Provenzano A, Genuardi M, Papi L: Evidence of a four-hit mechanism involving SMARCB1 and NF2 in schwannomatosis-associated schwannomas. <i>Hum Mutat<\/i> 29: 227-231, 2008","DOI":"10.1002\/humu.20679"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41) Christiaans I, Kenter SB, Brink HC, et al.: Germline SMARCB1 mutation and somatic NF2 mutations in familial multiple meningiomas. <i>J Med Genet<\/i> 48: 93-97, 2011","DOI":"10.1136\/jmg.2010.082420"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42) Piotrowski A, Xie J, Liu YF, et al.: Germline loss-of-function mutations in LZTR1 predispose to an inherited disorder of multiple schwannomas. <i>Nat Genet<\/i> 46: 182-187, 2014","DOI":"10.1038\/ng.2855"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43) Tamura R: Current Understanding of Neurofibromatosis Type 1, 2, and Schwannomatosis. <i>Int J Mol Sci<\/i> 22: 5850, 2021","DOI":"10.3390\/ijms22115850"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44) Pathmanaban ON, Sadler KV, Kamaly-Asl ID, et al.: Association of genetic predisposition with solitary schwannoma or meningioma in children and young adults. <i>JAMA Neurol<\/i> 74: 1123-1129, 2017","DOI":"10.1001\/jamaneurol.2017.1406"},{"key":"45","doi-asserted-by":"crossref","unstructured":"45) Smith MJ, Bowers NL, Bulman M, et al.: Revisiting neurofibromatosis type 2 diagnostic criteria to exclude LZTR1-related schwannomatosis. <i>Neurology<\/i> 88: 87-92, 2017","DOI":"10.1212\/WNL.0000000000003418"},{"key":"46","doi-asserted-by":"crossref","unstructured":"46) Smith MJ, Isidor B, Beetz C, et al.: Mutations in LZTR1 add to the complex heterogeneity of schwannomatosis. <i>Neurology<\/i> 84: 141-147, 2015","DOI":"10.1212\/WNL.0000000000001129"},{"key":"47","doi-asserted-by":"crossref","unstructured":"47) Kehrer-Sawatzki H, Farschtschi S, Mautner VF, Cooper DN: The molecular pathogenesis of schwannomatosis, a paradigm for the co-involvement of multiple tumour suppressor genes in tumorigenesis. <i>Hum Genet<\/i> 136: 129-148, 2017","DOI":"10.1007\/s00439-016-1753-8"},{"key":"48","doi-asserted-by":"crossref","unstructured":"48) Kehrer-Sawatzki H, Kluwe L, Friedrich RE, et al.: Phenotypic and genotypic overlap between mosaic NF2 and schwannomatosis in patients with multiple non-intradermal schwannomas. <i>Hum Genet<\/i> 137: 543-552, 2018","DOI":"10.1007\/s00439-018-1909-9"},{"key":"49","doi-asserted-by":"crossref","unstructured":"49) Louvrier C, Pasmant E, Briand-Suleau A, et al.: Targeted next-generation sequencing for differential diagnosis of neurofibromatosis type 2, schwannomatosis, and meningiomatosis. <i>Neuro Oncol<\/i> 20: 917-929, 2018","DOI":"10.1093\/neuonc\/noy009"},{"key":"50","doi-asserted-by":"crossref","unstructured":"50) Smith MJ, Bowers NL, Banks C, et al.: A deep intronic SMARCB1 variant associated with schwannomatosis. <i>Clin Genet<\/i> 97: 376-377, 2020","DOI":"10.1111\/cge.13637"},{"key":"51","doi-asserted-by":"crossref","unstructured":"51) Evans DG, King AT, Bowers NL, et al.: Identifying the deficiencies of current diagnostic criteria for neurofibromatosis 2 using databases of 2777 individuals with molecular testing. <i>Genet Med<\/i> 21: 1525-1533, 2019","DOI":"10.1038\/s41436-018-0384-y"},{"key":"52","doi-asserted-by":"crossref","unstructured":"52) King AT, Rutherford SA, Hammerbeck-Ward C, et al.: High-grade glioma is not a feature of neurofibromatosis Type 2 in the unirradiated patient. <i>Neurosurgery<\/i> 83: 193-196, 2018","DOI":"10.1093\/neuros\/nyx374"},{"key":"53","doi-asserted-by":"crossref","unstructured":"53) Evans DG, Freeman S, Gokhale C, et al.: Bilateral vestibular schwannomas in older patients: NF2 or chance? <i>J Med Genet<\/i> 52: 422-424, 2015","DOI":"10.1136\/jmedgenet-2014-102973"},{"key":"54","doi-asserted-by":"crossref","unstructured":"54) Rouleau GA, Merel P, Lutchman M, et al.: Alteration in a new gene encoding a putative membrane-organizing protein causes neuro-fibromatosis type 2. <i>Nature<\/i> 363: 515-521, 1993","DOI":"10.1038\/363515a0"},{"key":"55","doi-asserted-by":"crossref","unstructured":"55) Trofatter JA, MacCollin MM, Rutter JL, et al.: A novel moesin-, ezrin-, radixin-like gene is a candidate for the neurofibromatosis 2 tumor suppressor. <i>Cell<\/i> 75: 826, 1993","DOI":"10.1016\/0092-8674(93)90406-G"},{"key":"56","doi-asserted-by":"crossref","unstructured":"56) Knudson AG: Mutation and cancer: statistical study of retinoblastoma. <i>Proc Natl Acad Sci U S A<\/i> 68: 820-823, 1971","DOI":"10.1073\/pnas.68.4.820"},{"key":"57","doi-asserted-by":"crossref","unstructured":"57) Woods R, Friedman JM, Evans DGR, Baser ME, Joe H: Exploring the &quot;two-hit hypothesis&quot; in NF2: tests of two-hit and three-hit models of vestibular schwannoma development. <i>Genet Epidemiol<\/i> 24: 265-272, 2003","DOI":"10.1002\/gepi.10238"},{"key":"58","unstructured":"58) Ruttledge MH, Andermann AA, Phelan CM, et al.: Type of mutation in the neurofibromatosis type 2 gene (NF2) frequently determines severity of disease. <i>Am J Hum Genet<\/i> 59: 331-342, 1996"},{"key":"59","doi-asserted-by":"crossref","unstructured":"59) Selvanathan SK, Shenton A, Ferner R, et al.: Further genotype-phenotype correlations in neurofibromatosis 2. <i>Clin Genet<\/i> 77: 163-170, 2010","DOI":"10.1111\/j.1399-0004.2009.01315.x"},{"key":"60","doi-asserted-by":"crossref","unstructured":"60) Smith MJ, Higgs JE, Bowers NL, et al.: Cranial meningiomas in 411 neurofibromatosis type 2 (NF2) patients with proven gene mutations: clear positional effect of mutations, but absence of female severity effect on age at onset. <i>J Med Genet<\/i> 48: 261-265, 2011","DOI":"10.1136\/jmg.2010.085241"},{"key":"61","doi-asserted-by":"crossref","unstructured":"61) Evans DGR, Birch JM, Ramsden RT: Paediatric presentation of type 2 neurofibromatosis. <i>Arch Dis Child<\/i> 81: 496-499, 1999","DOI":"10.1136\/adc.81.6.496"},{"key":"62","doi-asserted-by":"crossref","unstructured":"62) Ruggieri M, Iannetti P, Polizzi A, et al.: Earliest clinical manifestations and natural history of neurofibromatosis type 2 (NF2) in childhood: a study of 24 patients. <i>Neuropediatrics<\/i> 36: 21-34, 2005","DOI":"10.1055\/s-2005-837581"},{"key":"63","doi-asserted-by":"crossref","unstructured":"63) Catas\u00fas N, Garcia B, Galv\u00e1n-Femen\u00eda I, et al.: Revisiting the UK Genetic Severity Score for NF2: a proposal for the addition of a functional genetic component. <i>J Med Genet<\/i> 59: 678-686, 2022","DOI":"10.1136\/jmedgenet-2020-107548"},{"key":"64","doi-asserted-by":"crossref","unstructured":"64) Halliday D, Emmanouil B, Pretorius P, et al.: Genetic Severity Score predicts clinical phenotype in NF2. <i>J Med Genet<\/i> 54: 657-664, 2017","DOI":"10.1136\/jmedgenet-2017-104519"},{"key":"65","doi-asserted-by":"crossref","unstructured":"65) Hexter A, Jones A, Joe H, et al.: Clinical and molecular predictors of mortality in neurofibromatosis 2: a UK national analysis of 1192 patients. <i>J Med Genet<\/i> 52: 699-705, 2015","DOI":"10.1136\/jmedgenet-2015-103290"},{"key":"66","doi-asserted-by":"crossref","unstructured":"66) Evans DG, Huson SM, Donnai D, et al.: A genetic study of type 2 neurofibromatosis in the United Kingdom. I. Prevalence, mutation rate, fitness, and confirmation of maternal transmission effect on severity. <i>J Med Genet<\/i> 29: 841-846, 1992","DOI":"10.1136\/jmg.29.12.841"},{"key":"67","doi-asserted-by":"crossref","unstructured":"67) Evans DGR, Moran A, King A, Saeed S, Gurusinghe N, Ramsden R: Incidence of vestibular schwannoma and neurofibromatosis 2 in the North West of England over a 10-year period: higher incidence than previously thought. <i>Otol Neurotol<\/i> 26: 93-97, 2005","DOI":"10.1097\/00129492-200501000-00016"},{"key":"68","doi-asserted-by":"crossref","unstructured":"68) Parry DM, Eldridge R, Kaiser-Kupfer MI, Bouzas EA, Pikus A, Patronas N: Neurofibromatosis 2 (NF2): clinical characteristics of 63 affected individuals and clinical evidence for heterogeneity. <i>Am J Med Genet<\/i> 52: 450-461, 1994","DOI":"10.1002\/ajmg.1320520411"},{"key":"69","doi-asserted-by":"crossref","unstructured":"69) Bernards A, Gusella JF: The importance of genetic mosaicism in human disease. <i>N Engl J Med<\/i> 331: 1447-1449, 1994","DOI":"10.1056\/NEJM199411243312110"},{"key":"70","doi-asserted-by":"crossref","unstructured":"70) Evans DG, Wallace AJ, Wu CL, Trueman L, Ramsden RT, Strachan T: Somatic mosaicism: a common cause of classic disease in tumor-prone syndromes? Lessons from type 2 neurofibromatosis. <i>Am J Hum Genet<\/i> 63: 727-736, 1998","DOI":"10.1086\/302004"},{"key":"71","doi-asserted-by":"crossref","unstructured":"71) Kluwe L, Mautner V, Heinrich B, et al.: Molecular study of frequency of mosaicism in neurofibromatosis 2 patients with bilateral vestibular schwannomas. <i>J Med Genet<\/i> 40: 109-114, 2003","DOI":"10.1136\/jmg.40.2.109"},{"key":"72","doi-asserted-by":"crossref","unstructured":"72) Teranishi Y, Miyawaki S, Hongo H, et al.: Targeted deep sequencing of DNA from multiple tissue types improves the diagnostic rate and reveals a highly diverse phenotype of mosaic neurofibromatosis type 2. <i>J Med Genet<\/i> 58: 701-711, 2021","DOI":"10.1136\/jmedgenet-2020-106973"},{"key":"73","doi-asserted-by":"crossref","unstructured":"73) Evans DGR, Ramsden RT, Shenton A, et al.: Mosaicism in neurofibromatosis type 2: an update of risk based on uni\/bilaterality of vestibular schwannoma at presentation and sensitive mutation analysis including multiple ligation-dependent probe amplification. <i>J Med Genet<\/i> 44: 424-428, 2007","DOI":"10.1136\/jmg.2006.047753"},{"key":"74","doi-asserted-by":"crossref","unstructured":"74) Halliday D, Emmanouil B, Evans DGR: Updated protocol for genetic testing, screening and clinical management of individuals at risk of NF2-related schwannomatosis. <i>Clin Genet<\/i> 103: 540-552, 2023","DOI":"10.1111\/cge.14310"},{"key":"75","doi-asserted-by":"crossref","unstructured":"75) Perez-Becerril C, Burghel GJ, Hartley C, Rowlands CF, Evans DG, Smith MJ: Improved sensitivity for detection of pathogenic variants in familial NF2-related schwannomatosis. <i>J Med Genet<\/i> 61: 452-458, 2024","DOI":"10.1136\/jmg-2023-109586"},{"key":"76","doi-asserted-by":"crossref","unstructured":"76) Radtke HB, Bergner AL, Goetsch AL, McGowan C, Panzer K, Cannon A: Genetic counseling for neurofibromatosis 1, neurofibromatosis 2, and schwannomatosis-Practice resource of the National Society of Genetic Counselors. <i>J Genet Couns<\/i> 29: 692-714, 2020","DOI":"10.1002\/jgc4.1303"},{"key":"77","doi-asserted-by":"crossref","unstructured":"77) Evans DG, Bowers NL, Tobi S, et al.: Schwannomatosis: a genetic and epidemiological study. <i>J Neurol Neurosurg Psychiatry<\/i> 89: 1215-1219, 2018","DOI":"10.1136\/jnnp-2018-318538"},{"key":"78","doi-asserted-by":"crossref","unstructured":"78) Louis DN, Perry A, Wesseling P, et al.: The 2021 WHO Classification of Tumors of the central nervous system: a summary. <i>Neuro Oncol<\/i> 23: 1231-1251, 2021","DOI":"10.1093\/neuonc\/noab106"},{"key":"79","unstructured":"79) Hanemann CO, Blakeley JO, Nunes FP, et al.: Current status and recommendations for biomarkers and biobanking in neurofibromatosis. <i>Neurology<\/i> 87 (suppl 1): S40-S48, 2016"}],"container-title":["Neurologia medico-chirurgica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/nmc\/64\/8\/64_2024-0067\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,17]],"date-time":"2024-08-17T04:25:49Z","timestamp":1723868749000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/nmc\/64\/8\/64_2024-0067\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,15]]},"references-count":79,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.2176\/jns-nmc.2024-0067","relation":{},"ISSN":["0470-8105","1349-8029"],"issn-type":[{"value":"0470-8105","type":"print"},{"value":"1349-8029","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,15]]},"article-number":"2024-0067"}}